Performance Enhancement Drug Testing: The Challenges and Future Developments in the Olympics and Professional Athletics

The Olympic Games, a global celebration of athleticism and sportsmanship, unfortunately, tangle with the shadowy domain of Performance Enhancing Drugs (PEDs). Even with rigorous testing measures enforced by the International Olympic Committee (IOC), the controversies surrounding PEDs such as Human Growth Hormone (HGH), EPO, and Testosterone persist.

During the 2008 Summer Olympics, the Beijing Organizers amplified efforts to catch athletes overstepping the line. They implemented forty-one drug testing stations, and selected 4,500 participants at random to undergo drug tests. This move aimed to discourage the use of PEDs and encourage a level playing field.

Unfortunately, the inherent challenges in tracking PEDs persist, specifically with substances such as HGH. English biologist and endocrinologist, Peter Sonksen, amongst others, has been focussing on developing new methodologies to track PED use. His recent achievements include developing a test that accurately reflects HGH consumption.

Testing HGH directly presents difficulties as its secretion from the pituitary gland gets converted into derivative forms like Insulin-like Growth Factor One (IGF 1) within minutes. However, IGF 1 remains in the blood stream for four to ten hours and remains active when connected to a cell receptor for up to three days. Hence, new testing models, including those developed by Sonksen, monitor higher levels of IGF 1.

Despite the advancements in drug testing methodologies, combating PED usage remains a daunting task due to the innovatory nature of athletes and their trainers. They continuously evolve, seeking new avenues to enhance performance undetected. This continuous evolution creates a sort of arms race between the enforcement community and the perpetrators, with the latter seemingly remaining a step ahead.

Unsurprisingly, PED abuse, as was the case with American track and field athlete Marion Jones, often goes undetected. Evaluated over a hundred times before events, Jones never tested positive for PED use. However, she faced retroactive disqualifications, was stripped of her Olympic medals, and served a prison sentence after admitting to lying about her PED usage.

Banned substances continue to evolve, making them increasingly difficult to track. The secretive nature of these cheating athletes further complicates this issue. Techniques such as freezing samples, as proposed by World Anti-Doping President, John Fahey, may provide promising ways to combat undetected PED usage. The approach to freeze blood and urine samples for up to eight years allows the retesting of samples with any new tests that come up, making it potentially risky for athletes to use PEDs.

Additionally, the development of new tests such as testing of IGF 1 R3, peptide hormones, and clenbuterol shows promise. These substances mimic the physiological benefits of HGH, increasing their attractiveness for performance enhancement.

Amidst these ethical dilemmas, the legal and medical use of Testosterone and HGH for Hormone Replacement Therapies (HRT) needs consideration. Such treatments benefit adults over thirty with diagnosable and symptomatic deficiencies such as hypogonadism and hypopituitarism. HRT using Testosterone or HGH can have immense benefits - enhancing life quality and longevity. HRT services acknowledge a clinical need, and offer various tests to diagnose deficiencies and ascertain patient eligibility for treatments.

In conclusion, while the controversy of PED use and the constant endeavor to combat it continues, the scientific and medical community remains committed to developing new methodologies to detect and deter the use. At the same time, the legal and beneficial use of Testosterone and HGH for HRT empowers those with deficiencies to lead a more rewarding life.

Word Count: 554